Last reviewed · How we verify
Terazosine
Terazosine is a Small molecule drug developed by University of Iowa. It is currently in Phase 2 development for Benign prostatic hyperplasia, Hypertensive disorder. Also known as: Group 2.
Terazosine is a small molecule that acts as an adrenergic receptor alpha-1 antagonist. It is used to treat conditions such as Benign Prostatic Hyperplasia and Hypertension.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Terazosine |
|---|---|
| Also known as | Group 2 |
| Sponsor | University of Iowa |
| Target | Ribosyldihydronicotinamide dehydrogenase [quinone], Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Approved indications
- Benign prostatic hyperplasia
- Hypertensive disorder
Common side effects
Key clinical trials
- Terazosin And Metabolic Energetics in Parkinson's Disease (PHASE2)
- Terazosin for Dementia With Lewy Bodies (PHASE1, PHASE2)
- Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (EARLY_PHASE1)
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
- Terazosin and Parkinson's Disease Extension Study (PHASE2)
- Terazosin And Metabolic Engagement in Parkinson's Disease (PHASE1, PHASE2)
- Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (PHASE3)
- Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terazosine CI brief — competitive landscape report
- Terazosine updates RSS · CI watch RSS
- University of Iowa portfolio CI
Frequently asked questions about Terazosine
What is Terazosine?
What is Terazosine used for?
Who makes Terazosine?
Is Terazosine also known as anything else?
What development phase is Terazosine in?
What does Terazosine target?
Related
- Target: All drugs targeting Ribosyldihydronicotinamide dehydrogenase [quinone], Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A
- Manufacturer: University of Iowa — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Benign prostatic hyperplasia
- Indication: Drugs for Hypertensive disorder
- Also known as: Group 2
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing